Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2015

View Archived Issues

RNA vaccine iHIVARNA-01 enters phase I trial in patients with HIV-1 infection

AbbVie presents key events from second quarter 2015

Heptares and Regeneron enter StaR protein collaboration

DNDi and Takeda collaborate on aminopyrazole series for visceral leishmaniasis

Cross-talk between Ret and Parkin has a key role in dopaminergic neuron survival

Catabasis Pharmaceuticals sponsors research into SREBP pathway involvement in lipid disorders

Boehringer Ingelheim signs license agreement with Hanmi for HM-61713

Oncolys BioPharma and Kagoshima University to jointly search for novel anti-HBV agents

Merck & Co. to acquire CEACAM-1 targeting immunotherapy developer cCAM Biotherapeutics

Bristol-Myers Squibb introduces ROR-gamma modulators

Pfizer reflects on key milestones of second quarter 2015

Qu Biologics begins phase II trial of QBECO SSI for ulcerative colitis

Inovio Pharmaceuticals begins trial of INO-5150 for prostate cancer

Patient-derived antibody is active against Middle East Respiratory Syndrome

A*STAR discloses MNK inhibitors

Novartis introduces PTP-2C inhibitors

Aurigene presents BET protein inhibitors

CIMA patents antifibrinolytics

Arena Pharmaceuticals begins phase II trial of APD-334

FDA clears IND for RXDX-107

Osteoprotegerin levels indicative of aortic valvular stenosis

New start-up Mereo BioPharma acquires programs from Novartis

Kyowa Hakko Kirin and BMS to study combination of mogamulizumab and nivolumab

Navidea receives NIH grants to study Manocept in atherosclerosis and rheumatoid arthritis

Astellas reports topline data from ACTIVE study of isavuconazole

FDA clears KaloBios' IND for KB-003 for chronic myelomonocytic leukemia

FDA accepts NDA for ZS-9 in hyperkalemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...